Advertisement
UK markets open in 4 hours 48 minutes
  • NIKKEI 225

    38,454.38
    -380.72 (-0.98%)
     
  • HANG SENG

    18,567.05
    +87.68 (+0.47%)
     
  • CRUDE OIL

    78.09
    -0.29 (-0.37%)
     
  • GOLD FUTURES

    2,316.50
    -7.70 (-0.33%)
     
  • DOW

    38,884.26
    +31.99 (+0.08%)
     
  • Bitcoin GBP

    50,219.10
    -835.21 (-1.64%)
     
  • CMC Crypto 200

    1,296.96
    -68.16 (-4.99%)
     
  • NASDAQ Composite

    16,332.56
    -16.69 (-0.10%)
     
  • UK FTSE All Share

    4,522.99
    +53.90 (+1.21%)
     

Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024

Altimmune, Inc
Altimmune, Inc

GAITHERSBURG, Md., March 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2023 financial results on Wednesday, March 27, 2024 and will provide a business update.

Altimmune management will host a conference call at 8:30 am E.T. on March 27 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors.

Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months.

ADVERTISEMENT

About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation therapeutics for the treatment of obesity and liver diseases. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH). In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Investor Contact:
Richard Eisenstadt                                                        
Chief Financial Officer                                                 
Phone: 240-654-1450                                                        
reisenstadt@altimmune.com

Media Contact:
Danielle Cantey
Inizio Evoke Comms
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com